Quick Summary:
Discover the potential in the ever-expanding Plasma Protease C1-inhibitor Treatment Market with our comprehensive market research report. Estimated at US$3.8 Billion in 2022, this market is poised for significant growth over the next eight years, projecting a robust future with a revised size of US$16.1 Billion by 2030.
Dissecting key segments such as C1-Inhibitor and Kallikrein Inhibitor (Kalbitor), our report provides an in-depth view of trends and growth trajectories, guiding your strategic planning and decision-making processes. Don't miss out on understanding the market dynamics in the U.S., China, Japan, Canada, and Europe, with the U.S. market alone estimated at $1.1 Billion in 2022. The report further includes insights about key competitors such as AbbVie, Alexion, Argenx amongst others, enabling you to stay ahead in this emerging market. With market updates for a year, interactive peer collaborations, and access to our digital archives, we ensure you're always at the forefront of this industry revolution.
Global Plasma Protease C1-inhibitor Treatment Market to Reach $16.1 Billion by 2030
The global market for Plasma Protease C1-inhibitor Treatment estimated at US$3.8 Billion in the year 2022, is projected to reach a revised size of US$16.1 Billion by 2030, growing at a CAGR of 20% over the analysis period 2022-2030. C1-Inhibitor, one of the segments analyzed in the report, is projected to record 18.2% CAGR and reach US$7.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Kallikrein Inhibitor (Kalbitor) segment is readjusted to a revised 20.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 19.1% CAGR
The Plasma Protease C1-inhibitor Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 19.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.7% and 17.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.Select Competitors (Total 46 Featured) -
- AbbVie
- Alexion
- Argenx
- Bluebird Bio
- Bristol-Myers Squibb/Celgene
- CSL Limited
- FibroGen
- Gilead
- GlaxoSmithKline
- Novartis
- Pharming Group N.V.
- Sanquin
- Shire plc
- Vertex
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Plasma Protease C1-inhibitor Treatment?
What is the growth rate of the Global Market for Plasma Protease C1-inhibitor Treatment?
What is the forecasted size of the Global Market for Plasma Protease C1-inhibitor Treatment?
Who are the key companies in the Global Market for Plasma Protease C1-inhibitor Treatment?
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | September 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 3.8 Billion |
| Forecasted Market Value ( USD | $ 16.1 Billion |
| Compound Annual Growth Rate | 19.8% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie
- Alexion
- Argenx
- Bluebird Bio
- Bristol-Myers Squibb/Celgene
- CSL Limited
- FibroGen
- Gilead
- GlaxoSmithKline
- Novartis
- Pharming Group N.V.
- Sanquin
- Shire plc
- Vertex
